RemeGen Biosciences, Inc.

22 articles about RemeGen Biosciences, Inc.

• RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

  4/3/2024

  RemeGen Co. Ltd., a commercial-stage biotechnology company, obtained Fast Track Designation by the United States Food and Drug Administration recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept, independently developed by RemeGen for the treatment of patients with primary Sjögren's syndrome.

• RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

  3/11/2024

  RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.

• World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

  2/2/2024

  RemeGen Co. Ltd., a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments.

• RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

  1/12/2024

  RemeGen Co. Ltd. announced recently that its independently developed mesothelin -targeting antibody-drug conjugate, RC88, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

• RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

  11/15/2023

  RemeGen Co., Ltd. is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session by the American College of Rheumatology.

• RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

  7/25/2023

  RemeGen Co., Ltd. has announced that their Phase II clinical study of telitacicept for the treatment of Primary Sjögren's Syndrome in adults has been published in top international medical journal Rheumatology.

• RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

  7/10/2023

  RemeGen Co., Ltd., a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics .

• Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China

  6/26/2023

  Innovent Biologics, Inc. and RemeGen Co., Ltd., announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® with RC88, a novel mesothelin-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China.

• RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

  6/5/2023

  RemeGen Co., Ltd., a fully-integrated commercial-stage biotechnology company, successfully obtained approval from The Stock Exchange of Hong Kong Limited on June 5, 2023 to remove the "B" marker from its stock short name as the Company's financial performance in 2022 met the market capitalization/revenue test under Rule 8.05 of the Hong Kong Stock Exchange's Listing Rules.

• ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

  6/5/2023

  RemeGen Co., Ltd., a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago.

• 

  Opinion: Hope on the Horizon for Sjogren’s Syndrome

  5/8/2023

  Despite multiple therapeutics approved to treat localized symptoms, there are currently no systemic therapies on the market for Sjogren’s syndrome.

• RemeGen Celebrates World Intellectual Property Day 2023

  4/26/2023

  RemeGen Co., Ltd., a commercial-stage biotechnology company, is celebrating World Intellectual Property Day 2023 which falls on April 26, the theme of which mirrors the critical importance RemeGen places on intellectual property rights for its accelerated innovation and creativity.

• On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

  2/28/2023

  RemeGen Co., Ltd. continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023's message of continuing to increase visibility and generate change for the millions of people globally living with a rare disease, their families and carers.

• RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

  12/13/2022

  RemeGen Co., Ltd., a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug conjugate, RC118 for injection, has been granted two orphan drug designations by the United States Food and Drug Administration for gastric cancer and pancreatic cancer.

• RemeGen Biosciences to Present New Data Updates in ACR 2022

  11/11/2022

  RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of the American College of Rheumatology (ACR) 2022, hosted from November 10th to 14th.

• RemeGen Biosciences to Attend ASN Kidney Week 2022

  11/3/2022

  RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of American Society of Nephrology Kidney Week 2022, hosted from November 3rd. to 6th.

• RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients

  11/1/2022

  RemeGen Co., Ltd., a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia gravis in Chinese patients, showing positive results.

• RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis

  10/12/2022

  RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG).

• RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

  5/24/2022

  RemeGen Co., Ltd., a commercial-stage biotechnology company, announced that three abstracts for disitamab vedotin have been selected for poster discussions by the 2022 American Society of Clinical Oncology Annual Meeting that will be held from June 3 to June 7 2022 in Chicago, USA.

• RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

  12/15/2021

  YANTAI, China , Dec. 14, 2021 /PRNewswire/ -- To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world. Since 19